Developer docs
API playgroundTry for free, no card

Search company profiles

Tillotts Pharma

Full company profile

uuid0008vo6

Namestring
Tillotts Pharma
Websiteurl
tillotts.com
Company typeenum
Private
Founded yearint
1986
Descriptiontext

Tillotts Pharma is a privately held international pharmaceutical company headquartered in Rheinfelden, Switzerland. Founded in 1986, the company has operated for nearly four decades and is part of the Zeria Group, a Japanese pharmaceutical parent. According to available firmographic data, Tillotts employs between 501 and 1,000 people, positioning it as a mid-cap pharmaceutical operation rather than a small specialty player or large multinational.

The company operates in the international pharmaceuticals sector, leveraging its Swiss base for cross-border regulatory and commercial activity. As a subsidiary of the Zeria Group, Tillotts Pharma's strategic positioning, capital structure, and corporate governance are tied to its parent's portfolio strategy. The company's website (tillotts.com) is its primary digital channel, although the source captured from it during data collection was a loader/verification page containing no substantive product, pipeline, or operational content. Consequently, specific therapeutic focus areas, product lines, manufacturing footprint, distribution model, and revenue mechanics cannot be detailed from the input data.

The business model is consistent with a traditional mid-cap international pharma: licensed and proprietary products commercialized across multiple markets, likely distributed via wholesalers, hospital systems, and specialist pharmacy channels. No pricing model, payer mix, customer segmentation, or channel data is available in the source material, so the revenue model description is limited to the standard sector template. Key analytical gaps include undisclosed revenue, absence of named products or pipeline assets, no disclosed geographic revenue mix, and no information on recent strategic transactions, leadership changes, or capital actions.

Short descriptiontext

Tillotts Pharma is a privately held international pharmaceutical company headquartered in Rheinfelden, Switzerland, founded in 1986 and operating as a subsidiary of the Zeria Group with 501-1,000 employees.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersRheinfelden, Switzerland
HQ citystring
Rheinfelden
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
pharmaceutical products, prescription medicines, specialty pharmaceuticals, pharmaceutical manufacturing, international pharma
Industry3 codes
1Primary Care & General Medicine Pharmaceuticals
CodeHLAIAAAAPrimaryYes
2Specialty Pharmaceutical Distributors
CodeHLAIAJABPrimaryNo
3Specialty Pharmacies (Complex/High-Cost Therapies)
CodeHLAFALACPrimaryNo
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceuticals
Cost components6 values
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Tillotts Pharma is an international pharmaceutical company headquartered in Rheinfelden, Switzerland, operating as part of the Zeria Group. The company develops, manufactures, and supplies pharmaceutical products. The website source material did not provide substantive product-level details.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
1Almirall
TypeDirect peer
Description

Spanish specialty pharmaceutical company focused on dermatology and gastrointestinal conditions. Comparable to Tillotts as a mid-sized European specialty pharma with international operations and branded product focus.

2Ferring Pharmaceuticals
TypeDirect peer
Description

Swiss-headquartered specialty pharmaceutical company focused on gastroenterology, reproductive health, and urology. Highly comparable to Tillotts in therapeutic focus (GI), Swiss origin, mid-sized private specialty pharma profile, and international commercial reach.

3Vifor Pharma
TypeDirect peer
Description

Swiss specialty pharmaceutical company headquartered near Zurich, focused on iron deficiency, nephrology, and gastroenterology. Comparable to Tillotts in Swiss base, specialty pharma positioning, and European-led international operations (now part of CSL Vifor).

4Dr. Falk Pharma
TypeDirect peer
Description

Privately-held European specialty pharma with a core focus on gastroenterology and hepatology. Directly comparable to Tillotts on therapeutic-area specialization, mid-sized specialty pharma model, and European commercial footprint.

5AbbVie
TypeBroad incumbent
Description

Global pharmaceutical major with a major gastroenterology franchise (Humira, Skyrizi, Rinvoq, Creon). Comparable as the dominant large-cap pharma player in Tillotts' therapeutic areas, representing both competitive pressure and potential M&A counterparty.

6Zeria Pharmaceutical
TypeBroad incumbent
Description

Japanese pharmaceutical group and Tillotts' parent company. Comparable as the corporate parent and direct portfolio peer in gastroenterology, with broader consumer healthcare and ethical pharma operations across Asia.

7Norgine
TypeDirect peer
Description

European specialty pharmaceutical company with a strong gastroenterology portfolio. Comparable to Tillotts in GI therapeutic focus, privately-held status, and European specialty pharma commercial model.

8Takeda Pharmaceutical
TypeBroad incumbent
Description

Japan-headquartered global pharmaceutical company with significant gastroenterology presence (Entyvio). Comparable as a major incumbent in the GI specialty space where Tillotts operates, with much broader scale and pipeline depth.

9Salix Pharmaceuticals
TypeDirect peer
Description

US-based specialty pharmaceutical company historically focused on gastroenterology (now part of Bausch Health). Comparable to Tillotts on GI therapeutic focus and specialty pharma model, though with stronger US concentration.

10Recordati
TypeDirect peer
Description

Italian specialty pharmaceutical group with significant gastroenterology and rare disease presence. Comparable to Tillotts in European specialty pharma positioning, branded product portfolio, and mid-cap international scale.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tillotts Pharma

Pharmaceuticalstillotts.com

Tillotts Pharma is a privately held international pharmaceutical company headquartered in Rheinfelden, Switzerland, founded in 1986 and operating as a subsidiary of the Zeria Group with 501-1,000 employees.

What Tillotts Pharma does

Tillotts Pharma is a privately held international pharmaceutical company headquartered in Rheinfelden, Switzerland. Founded in 1986, the company has operated for nearly four decades and is part of the Zeria Group, a Japanese pharmaceutical parent. According to available firmographic data, Tillotts employs between 501 and 1,000 people, positioning it as a mid-cap pharmaceutical operation rather than a small specialty player or large multinational.

The company operates in the international pharmaceuticals sector, leveraging its Swiss base for cross-border regulatory and commercial activity. As a subsidiary of the Zeria Group, Tillotts Pharma's strategic positioning, capital structure, and corporate governance are tied to its parent's portfolio strategy. The company's website (tillotts.com) is its primary digital channel, although the source captured from it during data collection was a loader/verification page containing no substantive product, pipeline, or operational content. Consequently, specific therapeutic focus areas, product lines, manufacturing footprint, distribution model, and revenue mechanics cannot be detailed from the input data.

The business model is consistent with a traditional mid-cap international pharma: licensed and proprietary products commercialized across multiple markets, likely distributed via wholesalers, hospital systems, and specialist pharmacy channels. No pricing model, payer mix, customer segmentation, or channel data is available in the source material, so the revenue model description is limited to the standard sector template. Key analytical gaps include undisclosed revenue, absence of named products or pipeline assets, no disclosed geographic revenue mix, and no information on recent strategic transactions, leadership changes, or capital actions.

Tillotts Pharma firmographics

Firmographics
Name
Tillotts Pharma
Website
https://tillotts.com
Company type
Private
Founded year
1986
Headcount range
251–500 employees
Short description
Tillotts Pharma is a privately held international pharmaceutical company headquartered in Rheinfelden, Switzerland, founded in 1986 and operating as a subsidiary of the Zeria Group with 501-1,000 employees.
Ownership category
akta.pro rank

Tillotts Pharma industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro primary industry
Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
akta.pro secondary industries
Specialty Pharmaceutical Distributors (HLAIAJAB), Specialty Pharmacies (Complex/High-Cost Therapies) (HLAFALAC)

Keywords

  • Pharmaceutical products
  • Prescription medicines
  • Specialty pharmaceuticals
  • Pharmaceutical manufacturing
  • International pharma

Where Tillotts Pharma is headquartered

Location

Headquarters

HQ city
Rheinfelden
HQ country
Switzerland
HQ region
Europe

Markets served

Tillotts Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Tillotts Pharma product offering

Product offering

Core offering

Tillotts Pharma is an international pharmaceutical company headquartered in Rheinfelden, Switzerland, operating as part of the Zeria Group. The company develops, manufactures, and supplies pharmaceutical products. The website source material did not provide substantive product-level details.

Differentiator

Problem solved

Functional benefit

Companies that use Tillotts Pharma

Customer profile

Ideal customer profiles1 record

Tillotts Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tillotts Pharma partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Tillotts Pharma competitors and assessment

Company assessment

Direct peers

  • Almirall: Spanish specialty pharmaceutical company focused on dermatology and gastrointestinal conditions. Comparable to Tillotts as a mid-sized European specialty pharma with international operations and branded product focus.
  • Ferring Pharmaceuticals: Swiss-headquartered specialty pharmaceutical company focused on gastroenterology, reproductive health, and urology. Highly comparable to Tillotts in therapeutic focus (GI), Swiss origin, mid-sized private specialty pharma profile, and international commercial reach.
  • Vifor Pharma: Swiss specialty pharmaceutical company headquartered near Zurich, focused on iron deficiency, nephrology, and gastroenterology. Comparable to Tillotts in Swiss base, specialty pharma positioning, and European-led international operations (now part of CSL Vifor).
  • Dr. Falk Pharma: Privately-held European specialty pharma with a core focus on gastroenterology and hepatology. Directly comparable to Tillotts on therapeutic-area specialization, mid-sized specialty pharma model, and European commercial footprint.
  • Norgine: European specialty pharmaceutical company with a strong gastroenterology portfolio. Comparable to Tillotts in GI therapeutic focus, privately-held status, and European specialty pharma commercial model.
  • Salix Pharmaceuticals: US-based specialty pharmaceutical company historically focused on gastroenterology (now part of Bausch Health). Comparable to Tillotts on GI therapeutic focus and specialty pharma model, though with stronger US concentration.
  • Recordati: Italian specialty pharmaceutical group with significant gastroenterology and rare disease presence. Comparable to Tillotts in European specialty pharma positioning, branded product portfolio, and mid-cap international scale.

Broad incumbents

  • AbbVie: Global pharmaceutical major with a major gastroenterology franchise (Humira, Skyrizi, Rinvoq, Creon). Comparable as the dominant large-cap pharma player in Tillotts' therapeutic areas, representing both competitive pressure and potential M&A counterparty.
  • Zeria Pharmaceutical: Japanese pharmaceutical group and Tillotts' parent company. Comparable as the corporate parent and direct portfolio peer in gastroenterology, with broader consumer healthcare and ethical pharma operations across Asia.
  • Takeda Pharmaceutical: Japan-headquartered global pharmaceutical company with significant gastroenterology presence (Entyvio). Comparable as a major incumbent in the GI specialty space where Tillotts operates, with much broader scale and pipeline depth.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks3 records

Key highlights5 records

Customer concentration

Tillotts Pharma social profiles

Digital presence

Tillotts Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tillotts Pharma leadership team

Management profile

Number of profiles

Tillotts Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tillotts Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tillotts Pharma

What does Tillotts Pharma do?

Tillotts Pharma is an international pharmaceutical company headquartered in Rheinfelden, Switzerland, operating as part of the Zeria Group. The company develops, manufactures, and supplies pharmaceutical products. The website source material did not provide substantive product-level details.

When was Tillotts Pharma founded?

Tillotts Pharma was founded in 1986. It employs 251 to 500 people.

Where is Tillotts Pharma based?

Tillotts Pharma is headquartered in Rheinfelden, Switzerland, in the Europe region.

Who are Tillotts Pharma's main competitors?

Direct peers on record are Almirall, Ferring Pharmaceuticals, Vifor Pharma, Dr. Falk Pharma, Norgine, Salix Pharmaceuticals and Recordati. Broad incumbents are AbbVie, Zeria Pharmaceutical and Takeda Pharmaceutical.

Does Tillotts Pharma have an API?

No public API is recorded for Tillotts Pharma.

What industry is Tillotts Pharma in?

Tillotts Pharma's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals, with a secondary code of HLAIAJAB, Specialty Pharmaceutical Distributors. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTillotts Pharma and TVM Capital Life Science Announce Formation of Mage Biologics to Develop Innovative Oral Antibody Therapy for Ulcerative ColitisTVM Capital Life Science and Tillotts Pharma announced a joint investment of up to $28 million in Mage Biologics, a U.S. biotech developing an oral monoclonal antibody for ulcerative colitis. The antibody, derived from a collaboration with Numab Therapeutics, uses Tillotts' sustained-release approach for local intestinal delivery. Clinical trial application is planned for 2024.PR NewswireTillotts Pharma in Germany Dedicated to Gastrointestinal HealthTillotts Pharma, a Swiss specialty pharmaceutical company focused on gastrointestinal diseases, opened its Berlin office in January 2017 under General Manager Magdalena Kritikos, planning to build a 20-person team to serve the German market. The company markets treatments including Entocort for Crohn's disease, Asacol for ulcerative colitis, and VistaPrep for bowel preparation, with products available in over 65 countries worldwide. Tillotts Pharma AG, headquartered in Rheinfelden, Switzerland, is an affiliate of the Japanese Zeria Group and has been dedicated to digestive health for over 30 years.PR NewswireTillotts Pharma AG's Parent Company Zeria Pharmaceutical Launches Zentacort® 3mg Capsules in Japan for Treatment in Crohn's DiseaseZeria Pharmaceutical Co., Ltd launched Zentacort® 3mg capsules in Japan on November 29, 2016, for the treatment of mild to moderate active Crohn's Disease, following regulatory approval on September 28, 2016. AstraZeneca initiated development of the drug in December 2010 following a request from the Japanese Ministry of Health, Labour and Welfare, and the worldwide rights to Entocort™ (except the USA) were acquired by Tillotts Pharma, a wholly-owned subsidiary of Zeria, in July 2015. The drug is now listed on Japan's National Health Insurance drug reimbursement price list at 256.90 yen per 100-capsule bottle.PR NewswireTillotts Pharma AG Introduces the New Technology OPTICORE™ (OPTImized COlonic RElease) for Colonic Targeting of Active Molecules for the Treatment of Any Colon DiseaseTillotts Pharma AG introduced its OPTICORE™ coating technology for colonic drug delivery at the 2016 annual meeting of the American Association of Pharmaceutical Scientists. The technology uses a dual trigger system combining pH-sensitive and enzyme-sensitive coatings with an inner accelerator layer to enable precise drug release at the ileo-colonic junction, addressing inter- and intra-individual variability in gastrointestinal physiology. The system is particularly suited for larger single-unit formulations targeting colon diseases like ulcerative colitis and has been successfully applied to tablets and capsules.AstrazenecaAstraZeneca completes agreement with Tillotts Pharma for EntocortAstraZeneca completed its agreement with Tillotts Pharma AG for the divestment of global rights outside the US to Entocort, a gastroenterology medicine used for mild to moderate Crohn's disease and ulcerative colitis. Tillotts paid $215 million for the rights to sell and develop Entocort capsules and enema formulations outside the US, with no transfer of employees or facilities involved. The transaction reinforces AstraZeneca's strategic focus on three main therapy areas and will be reported in Other Operating Income for 2015, without impacting its financial guidance.AstrazenecaAstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma for EntocortAstraZeneca has agreed to divest global rights outside the US for its gastroenterology drug Entocort to Tillotts Pharma AG, part of the Zeria Group, for $215 million as part of its strategic focus on selected therapy areas. Tillotts will acquire rights to sell and develop Entocort capsule and enema formulations, with the transaction expected to complete in the second half of 2015 subject to customary closing conditions. The drug generated $53 million in sales outside the US in 2014 and is currently available in over 40 countries, with a regulatory submission for Japan anticipated in the coming months.GlobeNewswireAgreement with Tillotts on EntocortAstraZeneca agreed to sell global rights to Entocort outside the US to Tillotts Pharma for $215 million. The deal, expected to close in H2 2015, does not affect AstraZeneca's 2015 financial guidance. A regulatory submission for Entocort in Japan is anticipated in coming months.GlobeNewswireDGAP-News: Cancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and JapanCancer Prevention Pharmaceuticals and Tillotts Pharma signed an exclusive licensing agreement for CPP-1X/sulindac in Europe and Japan for treating familial adenomatous polyposis. The deal includes upfront and milestone payments, with CPP potentially receiving over $100 million, including royalties escalating to double digits. The agreement can be expanded to additional indications.GlobeNewswireCancer Prevention Pharmaceuticals, Inc. and Tillotts Pharma AG Sign Licensing Agreement for CPP-1X/sulindac in Europe and JapanCancer Prevention Pharmaceuticals and Tillotts Pharma signed an exclusive licensing agreement for CPP-1X/sulindac in Europe and Japan for FAP and GI conditions. The deal includes upfront and milestone payments, with CPP potentially receiving over $100 million and royalties escalating to double digits. The agreement can be expanded to additional indications.